About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Allergan Announces Favorable CAFC Decision | Main | Dow Fires Executives Involved in "Rogue" Buyout Negotiations »

April 13, 2007

Milestone Achieved by Array BioPharma

Joblogo_2     By Jason Derry --

Array BioPharma has announced that AstraZeneca has dosed a patient with its MEK inhibitor, ARRY-704, in a Phase I clinical trial. By dosing the first patient, Array BioPharma is now entitled to a $2 million milestone payment from AstraZeneca. ARRY-704 is an orally active MEK-inhibitor with tumor suppressive activity.  Earlier this week, Array BioPharma announced that it has filed an Investigational New Drug (IND) application for ARRY-797, a p38 inhibitor, and plans to initiate Phase 1 clinical trials in cancer patients.

Contentpagelogo240x101

Posted at 03:33 PM in Licensing |

Comments

The comments to this entry are closed.

January 2025

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

Categories

Archives

More...